MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Bentamapimod

CAS No. : 848344-36-5

MCE 国际站：Bentamapimod

产品活性：Bentamapimod (AS 602801) 是一种ATP竞争性的 JNK 抑制剂，作用于 JNK1，JNK2 和 JNK3，IC₅₀ 分别为 80 nM，90 nM 和 230 nM。

研究领域：MAPK/ERK Pathway

作用靶点：JNK

In Vitro: Bentamapimod (AS 602801) treatment induces cell death and accordingly decreased the number of viable cells in all three cell lines in a dose-dependent manner, suggesting that Bentamapimod (AS 602801) may have selective cytotoxic activity against neoplastic cells. Bentamapimod (AS 602801) exhibits cytotoxicity against both serum-cultured non-stem cancer cells and cancer stem cells derived from human pancreatic cancer, non-small cell lung cancer, ovarian cancer and glioblastoma at concentrations that did not decrease the viability of normal human fibroblasts. Bentamapimod (AS 602801) also inhibits the self-renewal and tumor-initiating capacity of cancer stem cells surviving Bentamapimod (AS 602801) treatment.

In Vivo: Treatment of nude mice bearing xenografts biopsied from women with endometriosis (BWE) with 30 mg/kg Bentamapimod (AS 602801) causes 29% regression of lesion. Medroxyprogesterone acetate (MPA) or progesterone (PR) alone did not cause regression of BWE lesions, but combining 10 mg/kg Bentamapimod (AS 602801) with MPA caused 38% lesion regression. In human endometrial organ cultures (from healthy women), treatment with Bentamapimod (AS 602801) or MPA reduced matrix metalloproteinase-3 (MMP-3) release into culture medium. In organ cultures established with BWE, PR or MPA failed to inhibit MMP-3 secretion, whereas AS 602801 alone or MPA + Bentamapimod (AS 602801) suppresses MMP-3 production. In an autologous rat endometriosis model, AS 602801 causes 48% regression of lesions compared to GnRH antagonist Antide (84%). Bentamapimod (AS 602801) reduces inflammatory cytokines in endometriotic lesions, while levels of cytokines in ipsilateral horns are unaffected. Furthermore, Bentamapimod (AS 602801) enhances natural killer cell activity, without apparent negative effects on uterus.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Parkinson's Disease Compound Library  |  Anti-Obesity Compound Library  |  Transcription Factor-Targeted Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Antidepressant Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Pain-Related Compound Library  |  JTP10-△-R9 TFA  |  J30-8  |  Isovitexin  |  Threo-Chloramphenicol-d₆  |  JNK3 inhibitor-8  |  JNK3 inhibitor-6  |  JNK3 inhibitor-4  |  Nrf2/HO-1 activator 2  |  JNK3 inhibitor-7  |  JNK-IN-8  |  WHI-P258  |  Tomatidine hydrochloride  |  Astragaloside IV  |  Isodorsmanin A  |  JNK Inhibitor VIII  |  MPT0B392  |  (-)-Zuonin A  |  Indirubin-3′-oxime  |  AEG3482  |  Aloisine A  |  Lucidone  |  YL5084  |  JNK3 inhibitor-1  |  L-JNKI-1  |  SR-3306  |  BI-78D3  |  Chloramphenicol  |  SX 011

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。